Benefits of annual chemotherapeutic control of schistosomiasis on the development of protective immunity.
Adaptive Immunity
Adolescent
Animals
Anthelmintics
/ therapeutic use
Antibodies, Helminth
/ blood
Child
Female
Hematuria
/ pathology
Humans
Immunoglobulin G
/ metabolism
Immunoglobulin Isotypes
/ blood
Longitudinal Studies
Male
Ovum
/ cytology
Praziquantel
/ therapeutic use
Prevalence
Schistosoma haematobium
/ growth & development
Schistosomiasis haematobia
/ drug therapy
Treatment Outcome
Zimbabwe
/ epidemiology
Antibodies
Immunity
MDA
Praziquantel
Schistosomiasis
Treatment
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
04 Mar 2019
04 Mar 2019
Historique:
received:
27
10
2017
accepted:
13
02
2019
entrez:
6
3
2019
pubmed:
6
3
2019
medline:
17
4
2019
Statut:
epublish
Résumé
Schistosomiasis is a devastating parasitic disease. The mainstay of schistosomiasis control is by praziquantel treatment. The study aimed to determine benefits of annual chemotherapy of schistosomiasis on development of protective immunity in school children in a selected endemic rural area in Zimbabwe. Urine specimens from 212 school children (7-13 years) were collected and examined to determine prevalence, intensity and reinfection of S.haematobium at baseline, 6 weeks and 2 years following annual rounds of praziquantel treatment. Blood samples from the participants were assayed for total and S. haematobium (Sh13)-specific antibodies before and 2 years after annual rounds of treatment. Annual treatment reduced the prevalence of S. haematobium infection (p < 0.05) from 23.1% at baseline to 0.47% after 2 years. Overall cure rate was 97.8%. Intensity of infection declined (p < 0.05) from 15.9 eggs/10 ml urine at baseline to 2 eggs/10 ml urine. After two years, overall rate of reinfection was 0.96%. At baseline, total IgG4 was higher in S. haematobium-infected children (p = 0.042) ,while all other immunoglobulins were within normal ranges. There was an increase in total IgG2 (p = 0.044) levels and a decrease in total IgG4 (p = 0.031) levels 2 years post-treatment; and no significant changes in other total immunoglobulins. Schistosoma-infected children at baseline showed an increase in anti-Sh13 IgG1 (p = 0.005) and a decrease in Sh13 IgG4 levels (p = 0.012) following treatment. Annual praziquantel treatment delivered to school children over 2 years significantly reduce prevalence, intensity of infection and reinfection of S. haematobium infection. Treatment was also observed to cause a reduction in schistosome-specific blocking IgG4 and an increase in Schistosoma-specific protecting IgG1.
Sections du résumé
BACKGROUND
BACKGROUND
Schistosomiasis is a devastating parasitic disease. The mainstay of schistosomiasis control is by praziquantel treatment. The study aimed to determine benefits of annual chemotherapy of schistosomiasis on development of protective immunity in school children in a selected endemic rural area in Zimbabwe.
METHODS
METHODS
Urine specimens from 212 school children (7-13 years) were collected and examined to determine prevalence, intensity and reinfection of S.haematobium at baseline, 6 weeks and 2 years following annual rounds of praziquantel treatment. Blood samples from the participants were assayed for total and S. haematobium (Sh13)-specific antibodies before and 2 years after annual rounds of treatment.
RESULTS
RESULTS
Annual treatment reduced the prevalence of S. haematobium infection (p < 0.05) from 23.1% at baseline to 0.47% after 2 years. Overall cure rate was 97.8%. Intensity of infection declined (p < 0.05) from 15.9 eggs/10 ml urine at baseline to 2 eggs/10 ml urine. After two years, overall rate of reinfection was 0.96%. At baseline, total IgG4 was higher in S. haematobium-infected children (p = 0.042) ,while all other immunoglobulins were within normal ranges. There was an increase in total IgG2 (p = 0.044) levels and a decrease in total IgG4 (p = 0.031) levels 2 years post-treatment; and no significant changes in other total immunoglobulins. Schistosoma-infected children at baseline showed an increase in anti-Sh13 IgG1 (p = 0.005) and a decrease in Sh13 IgG4 levels (p = 0.012) following treatment.
CONCLUSION
CONCLUSIONS
Annual praziquantel treatment delivered to school children over 2 years significantly reduce prevalence, intensity of infection and reinfection of S. haematobium infection. Treatment was also observed to cause a reduction in schistosome-specific blocking IgG4 and an increase in Schistosoma-specific protecting IgG1.
Identifiants
pubmed: 30832614
doi: 10.1186/s12879-019-3811-z
pii: 10.1186/s12879-019-3811-z
pmc: PMC6398226
doi:
Substances chimiques
Anthelmintics
0
Antibodies, Helminth
0
Immunoglobulin G
0
Immunoglobulin Isotypes
0
Praziquantel
6490C9U457
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
219Références
Trop Med Int Health. 2001 Jan;6(1):24-30
pubmed: 11263461
Mem Inst Oswaldo Cruz. 2001;96 Suppl:157-64
pubmed: 11586443
Trop Med Int Health. 2001 Oct;6(10):817-25
pubmed: 11679130
Acta Trop. 2002 May;82(2):139-46
pubmed: 12020886
Trop Med Int Health. 2003 Jun;8(6):561-8
pubmed: 12791062
Trends Parasitol. 2003 Nov;19(11):509-15
pubmed: 14580962
Trans R Soc Trop Med Hyg. 2004 Mar;98(3):139-41
pubmed: 15024922
Bull Soc Pathol Exot. 2004 Feb;97(1):7-11
pubmed: 15104149
Int J Parasitol. 2005 Jun;35(7):787-91
pubmed: 15925597
Eur J Immunol. 1992 Aug;22(8):2063-70
pubmed: 1639104
Lancet Infect Dis. 2006 Jul;6(7):411-25
pubmed: 16790382
J Immunol. 2006 Oct 15;177(8):5490-8
pubmed: 17015735
Bull World Health Organ. 2007 Feb;85(2):91-9
pubmed: 17308729
Acta Trop. 2007 Jun;102(3):165-71
pubmed: 17572368
J Infect Dis. 2007 Sep 1;196(5):659-69
pubmed: 17674306
J Infect Dis. 2008 Jul 15;198(2):167-75
pubmed: 18549316
Curr Opin Infect Dis. 2008 Dec;21(6):659-67
pubmed: 18978535
Nature. 1991 Jan 17;349(6306):243-5
pubmed: 1898985
BMJ. 2011 May 17;342:d2651
pubmed: 21586478
Parasit Vectors. 2012 Jun 07;5:108
pubmed: 22676052
Acta Trop. 2013 Nov;128(2):292-302
pubmed: 23022016
Parasitol Res. 2012 Nov;111(5):1871-7
pubmed: 23052781
PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2431
pubmed: 24069486
PLoS Negl Trop Dis. 2014 Aug 14;8(8):e3014
pubmed: 25121489
Wkly Epidemiol Rec. 2015 Jan 30;90(5):25-32
pubmed: 25638822
Parasit Vectors. 2015 Apr 10;8:215
pubmed: 25886292
Lancet. 2015 Aug 22;386(9995):743-800
pubmed: 26063472
PLoS Negl Trop Dis. 2016 Mar 02;10(3):e0003895
pubmed: 26934395
J Immunol. 1989 Jun 15;142(12):4422-7
pubmed: 2723436
Lancet Infect Dis. 2016 Sep;16(9):1065-1075
pubmed: 27286968
Am J Trop Med Hyg. 1985 Nov;34(6):1119-26
pubmed: 3938926
J Immunol. 1986 Mar 1;136(5):1859-63
pubmed: 3950405
Immunology. 1982 Aug;46(4):777-85
pubmed: 6179857
Am J Trop Med Hyg. 1984 Sep;33(5):862-71
pubmed: 6486295
Tropenmed Parasitol. 1982 Dec;33(4):227-8
pubmed: 7164164
Am J Trop Med Hyg. 1980 Mar;29(2):217-9
pubmed: 7369441
Am J Trop Med Hyg. 1995 Aug;53(2):167-70
pubmed: 7677219
Eur J Immunol. 1996 Jun;26(6):1365-70
pubmed: 8647218
Clin Chem. 1996 Jul;42(7):1064-7
pubmed: 8674189
J Infect Dis. 1997 Jul;176(1):304-7
pubmed: 9207389
Parasite Immunol. 1997 Jul;19(7):333-5
pubmed: 9278946
J Infect Dis. 1998 Jul;178(1):289-93
pubmed: 9652458
Trans R Soc Trop Med Hyg. 1998 Jul-Aug;92(4):386-9
pubmed: 9850386